The research study presented here is an intelligent take on Migraine Drugs Market Size by MRFR that explains important aspects such as competition, segmentation, and regional growth in great detaiL
The Global Migraine Drugs Market is expected to hold a value of USD 6.5 Billion by 2025 at a CAGR of 5.9%.Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds.The growth of the migraine drugs market is driven by various factors such as an increasing global geriatric population, rising prevalence of migraine, growing awareness about migraine in developing economies, rising R&D investment for the development of innovative drugs for the treatment of migraine, and increasing demand for better treatment methods for migraine.Some of the key players in the global migraine drugs market areAllergan Plc (Ireland)Alder Biopharmaceuticals Inc. (US)Pfizer Inc. (US)GlaxoSmithKline Plc (UK)Merck & Co. Inc. (US)Teva Pharmaceutical Industries Ltd (Israel)AstraZeneca Plc (UK)Johnson & Johnson Services Inc. (US)Amgen Inc (US)Eli Lilly and CompanyeNeura Incand OthersGEt an Amazing Information On https://www.medgadget.com/2019/10/migraine-drugs-market-therapeutics-industry-size-competitive-share-and-major-growth-drivers-to-reach-global-worth-of-usd-6-5-billion-by-2025-at-a-cagr-of-5-9.htmlMigraine is more common in women than men, majorly due to the fluctuations in the hormone levels. Approximately 12% of the US population suffered from migraine headaches in 2018. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.Market SegmentationThe global migraine drugs market has been segmented based on type, treatment, drug class, and end user.The global migraine drugs market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine.The global migraine drugs market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others.The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine.The global migraine drugs market has been segmented, on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.LIST OF TABLESTABLE 1 GLOBAL MIGRAINE DRUGS MARKET SYNOPSIS, 2019–2025TABLE 2 GLOBAL MIGRAINE DRUGS MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION)TABLE 3 GLOBAL MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2019–2025 (USD MILLION)TABLE 4 GLOBAL MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)TABLE 5 GLOBAL MIGRAINE DRUGS MARKET, BY END USER, 2019-2025 (USD MILLION)TABLE 6 GLOBAL MIGRAINE DRUGS MARKET, BY REGION, 2019–2025 (USD MILLION)…ContinuedBrowse Complete Premium Report Details @ https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379
Regional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is expected to be the largest market owing to the increasing prevalence of migraine and R&D by major players in the region. For instance, in September 2018, Eli Lilly and Company launched Emgality (galcanezumab-gnlm) injection (300 mg) for the preventive treatment of migraine in adults. It is the first drug to receive Food and Drug Administration (FDA) approval for decreasing the frequency of episodic cluster headache attacks. The migraine drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. About Market Research Future: Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.